Insulin Delivery Devices Market, by Product Type, Distribution Channel, and Geography - Global Trends, and Forecast, 2022 - 2028
Direct subcutaneous insulin injection are the most common form of drug delivery, using a needle and syringe. There are different types of insulin delivery devices available including, syringes, pens, jet injectors, and insulin pumps. Insulin can be packaged in vials (bottles), cartridges or prefilled pens. However, several disposable and reusable pen devices have been developed that provide options for delivering rapid insulins and insulin premixes. Type or dosage of insulin can be changed according to the requirements to meet the individual needs of the patient Manufacturers are focusing on designing products, which are cost effective for people with diabetes which is expected to propel the growth of the insulin delivery devices market. For instance, in July 2017, Becton, Dickinson and Company launched BD Viva pen needles, have a highly engineered needle tip design for improved comfort and considered as the most cost-effective option for insulin-injecting people with diabetes in the UK.
Market Dynamics
The market is gaining significant traction due to increasing prevalence of diabetes, and new innovations in terms of design. According to the World Health Organization, in 2021, an estimated 422 million adults are living with diabetes globally. The major spike in incidence of type 2 diabetes over the last decade is mainly attributed to rising prevalence of obesity. However, high cost of some insulin delivery devices is expected to be a restraining factor for the market growth. For instance, insulin analogs supplied in cartridges or prefilled pens have a higher per unit of insulin cost than insulin analogs supplied in vials. For example, one vial (1000 U) of insulin costs US$ 105.95, which equates to a cost of 10.6 cents per unit of insulin. Five prefilled insulin pens containing insulin glulisine (total of 1500 U) have a total cost of US$ 201.01, equating to a cost of 13.4 cents per unit of insulin (26% over the cost of insulin glulisine supplied in a vial).
Key features of the study:
This report provides in-depth analysis of the insulin delivery devices market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global insulin delivery devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans
Key companies covered as a part of this study include Novo Nordisk A/S, Becton, Dickinson and Company, Sanofi S.A.., F. Hoffmann-La Roche, Ltd., Eli Lilly and Company, Medtronic, Plc, Ypsomed Holding AG, Animas Corporation, and Insulet Corporation.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics.
The global insulin delivery devices market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of insulin delivery devices, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the insulin delivery devices market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
Global Insulin Delivery Devices Market, By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
Global Insulin Delivery Devices Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Insulin Delivery Devices Market, By Geography:
North America
By Country:
U.S.
Canada
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
China
India
Japan
ASEAN
Australia
South Korea
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
North Africa
Central Africa
South Africa
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Novo Nordisk A/S*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
Becton, Dickinson and Company
Sanofi S.A.
F. Hoffmann-La Roche, Ltd.
Eli Lilly and Company
Medtronic, Plc
Ypsomed Holding AG
Animas Corporation
Insulet Corporation
“*” marked represents similar segmentation in other categories in the respective section.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook